Envigo Opens its Doors for Business on 21 September
News Sep 24, 2015
Huntingdon Life Sciences, Harlan Laboratories and three subsidiaries have announced that the combined companies have re-branded as Envigo (pronounced En-vee-go.).
Brian Cass, CEO, commented: “Today we are delighted to officially re-brand as Envigo. This marks a significant milestone for the five companies that came together to create Envigo and demonstrates the great progress we have made in our integration. Our customers are increasingly seeking partners who can deliver a variety of services in a co-ordinated manner, and the breadth of Envigo’s offering strengthens our ability to deliver on that need.”
Envigo employs 3,800 people and has sales approaching $500 million. The company is a top-three provider of non-clinical research services and research models and services to the pharmaceutical, chemical and crop protection industries, as well as academic institutions and government agencies worldwide.
Since the announcement on 24 June 2015 that the five companies were combining to form Envigo customers have shown their support for the new company. Adrian Hardy, COO, added: “We have received very positive comments from customers to the on-going integration of our businesses and to our new name. Today we have become Envigo, and our goal is to establish the company as the number one partner for both customer service and scientific excellence.”
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE